- New York, NY-base S1 Biopharma (SXB) is set for its IPO of 2.75M shares of common stock at $12 - 14.
- The clinical stage biopharmaceutical firm develops therapies for sexual dysfunction. Its lead product candidate is Lorexys, a fixed-dose combination therapy for the treatment of female hypoactive sexual desire disorder (HSDD), currently in Phase 2 clinicals. Its second product candidate is Orexa for the treatment of male HSDD. The company expects to initiate a Phase 2a study in Q2 2015 and a Phase 2b trial in 2016.
- 2013 Performance: Operating Expenses: $1.8M (-131.1%); Net Loss: ($2.0M) (-144.0%); Cash Burn: ($719K) (-628.3%).
- 1H 2014 Performance: Operating Expenses: $1.6M (+74.5%); Net Loss: ($1.8M) (-93.3%); Cash Burn: ($838K) (-148.9%).
- ETFs: IBB, BIB, BIS (NYSEARCA:IPO)